Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.67B | $8.72B | $8.38B | $8.60B | $8.03B | $8.43B | $8.12B | $8.76B | $9.63B | $10.3B |
| Revenue growth | — | -9.8% | -3.9% | 2.6% | -6.7% | 5.1% | -3.7% | 7.8% | 9.9% | 6.7% |
| Operating income | -$566M | $102M | -$2.38B | -$203M | $676M | $450M | $454M | $963M | $1.55B | $1.81B |
| Operating margin | -5.9% | 1.2% | -28.4% | -2.4% | 8.4% | 5.3% | 5.6% | 11.0% | 16.1% | 17.7% |
| Net income | -$2.41B | $2.40B | -$4.14B | -$1.79B | -$560M | -$948M | -$225M | -$592M | -$46.0M | $157M |
| Net margin | -24.9% | 27.6% | -49.5% | -20.8% | -7.0% | -11.2% | -2.8% | -6.8% | -0.5% | 1.5% |
| EPS (diluted) | -$6.94 | $6.83 | -$11.81 | -$5.08 | -$1.58 | -$2.64 | -$0.62 | -$1.62 | -$0.13 | $0.42 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $2.09B | $2.29B | $1.50B | $1.50B | $1.11B | $1.43B | -$728M | $1.03B | $1.60B | $1.40B |
| Capital expenditures | $235M | $171M | $157M | $270M | $302M | $269M | $218M | $215M | $337M | $397M |
| Free cash flow | $1.85B | $2.12B | $1.34B | $1.23B | $809M | $1.16B | -$946M | $817M | $1.26B | $1.00B |
| Share buybacks | $0.00 | $0.00 | — | — | — | — | — | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $542M | $720M | $721M | $3.24B | $605M | $582M | $564M | $947M | $1.18B | $1.31B |
| Total assets | $43.5B | $37.5B | $32.5B | $33.9B | $31.2B | $29.2B | $25.7B | $27.4B | $26.5B | $26.4B |
| Total liabilities | $40.3B | $31.6B | $29.7B | $32.7B | $30.6B | $29.2B | $25.4B | $27.4B | $26.8B | $26.0B |
| Long-term debt | $29.8B | $25.2B | $24.1B | $24.7B | $23.9B | $22.7B | $20.3B | $21.9B | $18.9B | $20.6B |
| Shareholders' equity | $3.15B | $5.85B | $2.73B | $1.06B | $535M | -$106M | -$692M | -$1.02B | -$1.28B | -$554M |
| Retained earnings | -$5.13B | -$2.73B | -$5.66B | -$7.45B | -$8.01B | -$8.96B | -$9.19B | -$9.78B | -$9.82B | -$9.67B |
| Shares (wtd avg diluted) | 347M | 352M | 351M | 352M | 355M | 359M | 362M | 365M | 368M | 375M |
Every figure is extracted from Bausch Health Companies Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.